Cargando…
Development of Oral Sustained Release Rifampicin Loaded Chitosan Nanoparticles by Design of Experiment
Objective. The main objective of the present investigation was to develop and optimize oral sustained release Chitosan nanoparticles (CNs) of rifampicin by design of experiment (DOE). Methodology. CNs were prepared by modified emulsion ionic gelation technique. Here, inclusion of hydrophobic drug mo...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3759266/ https://www.ncbi.nlm.nih.gov/pubmed/24024034 http://dx.doi.org/10.1155/2013/370938 |
_version_ | 1782477229995851776 |
---|---|
author | Patel, Bhavin K. Parikh, Rajesh H. Aboti, Pooja S. |
author_facet | Patel, Bhavin K. Parikh, Rajesh H. Aboti, Pooja S. |
author_sort | Patel, Bhavin K. |
collection | PubMed |
description | Objective. The main objective of the present investigation was to develop and optimize oral sustained release Chitosan nanoparticles (CNs) of rifampicin by design of experiment (DOE). Methodology. CNs were prepared by modified emulsion ionic gelation technique. Here, inclusion of hydrophobic drug moiety in the hydrophilic matrix of polymer is applied for rifampicin delivery using CN. The 2(3) full-factorial design was employed by selecting the independent variables such as Chitosan concentration (X (1)), concentration of tripolyphosphate (X (2)), and homogenization speed (X (3)) in order to achieve desired particle size with maximum percent entrapment efficiency and drug loading. The design was validated by checkpoint analysis, and formulation was optimized using the desirability function. Results. Particle size, drug entrapment efficiency, and drug loading for the optimized batch were found to be 221.9 nm, 44.17 ± 1.98% W/W, and 42.96 ± 2.91% W/W, respectively. In vitro release data of optimized formulation showed an initial burst followed by slow sustained drug release. Kinetic drug release from CNs was best fitted to Higuchi model. Conclusion. Design of Experiment is an important tool for obtaining desired characteristics of rifampicin loaded CNs. In vitro study suggests that oral sustained release CNs might be an effective drug delivery system for tuberculosis. |
format | Online Article Text |
id | pubmed-3759266 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-37592662013-09-10 Development of Oral Sustained Release Rifampicin Loaded Chitosan Nanoparticles by Design of Experiment Patel, Bhavin K. Parikh, Rajesh H. Aboti, Pooja S. J Drug Deliv Research Article Objective. The main objective of the present investigation was to develop and optimize oral sustained release Chitosan nanoparticles (CNs) of rifampicin by design of experiment (DOE). Methodology. CNs were prepared by modified emulsion ionic gelation technique. Here, inclusion of hydrophobic drug moiety in the hydrophilic matrix of polymer is applied for rifampicin delivery using CN. The 2(3) full-factorial design was employed by selecting the independent variables such as Chitosan concentration (X (1)), concentration of tripolyphosphate (X (2)), and homogenization speed (X (3)) in order to achieve desired particle size with maximum percent entrapment efficiency and drug loading. The design was validated by checkpoint analysis, and formulation was optimized using the desirability function. Results. Particle size, drug entrapment efficiency, and drug loading for the optimized batch were found to be 221.9 nm, 44.17 ± 1.98% W/W, and 42.96 ± 2.91% W/W, respectively. In vitro release data of optimized formulation showed an initial burst followed by slow sustained drug release. Kinetic drug release from CNs was best fitted to Higuchi model. Conclusion. Design of Experiment is an important tool for obtaining desired characteristics of rifampicin loaded CNs. In vitro study suggests that oral sustained release CNs might be an effective drug delivery system for tuberculosis. Hindawi Publishing Corporation 2013 2013-08-18 /pmc/articles/PMC3759266/ /pubmed/24024034 http://dx.doi.org/10.1155/2013/370938 Text en Copyright © 2013 Bhavin K. Patel et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Patel, Bhavin K. Parikh, Rajesh H. Aboti, Pooja S. Development of Oral Sustained Release Rifampicin Loaded Chitosan Nanoparticles by Design of Experiment |
title | Development of Oral Sustained Release Rifampicin Loaded Chitosan Nanoparticles by Design of Experiment |
title_full | Development of Oral Sustained Release Rifampicin Loaded Chitosan Nanoparticles by Design of Experiment |
title_fullStr | Development of Oral Sustained Release Rifampicin Loaded Chitosan Nanoparticles by Design of Experiment |
title_full_unstemmed | Development of Oral Sustained Release Rifampicin Loaded Chitosan Nanoparticles by Design of Experiment |
title_short | Development of Oral Sustained Release Rifampicin Loaded Chitosan Nanoparticles by Design of Experiment |
title_sort | development of oral sustained release rifampicin loaded chitosan nanoparticles by design of experiment |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3759266/ https://www.ncbi.nlm.nih.gov/pubmed/24024034 http://dx.doi.org/10.1155/2013/370938 |
work_keys_str_mv | AT patelbhavink developmentoforalsustainedreleaserifampicinloadedchitosannanoparticlesbydesignofexperiment AT parikhrajeshh developmentoforalsustainedreleaserifampicinloadedchitosannanoparticlesbydesignofexperiment AT abotipoojas developmentoforalsustainedreleaserifampicinloadedchitosannanoparticlesbydesignofexperiment |